FOSTER CITY, Calif: On Nov 20th, 2017, Guangzhou Institute of Respiratory Disease of Guangzhou Medical University First Affiliated Hospital and MORE Health, Inc., hosted the monthly Grand Rounds with Famous Physicians. This academic event involved multiple hospitals and numerous medical professionals including top physicians from both China and the US.
The Grand Rounds invited Dr. Nanshan Zhong, Fellow of China Engineering Academy, and Dr. Rongchang Chen, Director of Guangzhou Institute of Respiratory Disease, to present cases. They were joined by Dr. Aaron Waxman from Harvard Medical School and Dr. Roham Zamanian from Stanford University Medical Center, as well as Dr. Zhancheng Gao, Professor at Peking University Affiliated People's Hospital. These leading experts in respiratory disease from both the US and China gave insightful case analysis and provided a thought-provoking academic discussion for all participants.
Dr. Zhong is a Fellow of China Engineering Academy, Professor in Pulmonology, Chief Physician and Director of State Key Laboratory of Respiratory Disease, Director of State Clinical Research Center of Respiratory Disease. He also served as former Chairman of China Medical Association and honorary Director of Guangzhou Institute of Respiratory Disease. He has been ranked as a top 10 scientist in China, and he achieved prominent notice with his discovery of SARS in 2003. The monthly Grand Rounds was founded by Dr. Zhong in 2011 to improve clinical care in pulmonology at the Guangzhou Institute of Respiratory Disease by sharing ideas and discussing clinical experiences with medical professionals across China and around the world.
Dr. Chen is a Professor in Pulmonology, Chief Physician and Director of Guangzhou Institute of Respiratory Disease. He also serves as the Associate Director of State Clinical Research Center of Respiratory Disease and member of Respiratory Disease Branch of China Medical Association.
Dr. Waxman is the Director of Pulmonary Vascular Diseases program at Brigham and Women's Hospital and associate professor at Harvard Medical School. Dr. Waxman graduated from Yale Medical School with a focus on pulmonary hypertension, right heart failure, thromboembolic disease and pulmonary vascular diseases. His research areas include the inflammatory mechanism of pulmonary vascular remodeling that leads to heart failure.
Dr. Zamanian is an Associate Professor of Medicine (Pulmonary and Critical Care Medicine) at Stanford University Medical Center, and Director of the Adult Pulmonary Arterial Hypertension program at the Vera Moulton Wall Center for pulmonary vascular diseases. His professional areas of interest are concentrated in pulmonary hypertension, pulmonary embolism, and heart failure.
Chinese physicians and students physically attended the Grand Rounds at Guangzhou Institute of Respiratory Disease and at Peking University Affiliated People's Hospital. The US physicians attended from their offices in California and Massachusetts. And MORE Health connected all of the participants with its online Physician Collaboration Platform. The event began with a live patient interview and physical examination, followed by remote case review and discussion among the experts from both China and the US.
To increase the efficiency of the conference, all of the participating physicians had the opportunity to review the labs and medical images before the Grand Rounds through MORE Health's platform, and the US physicians had provided their initial evaluation of the case. During the video discussion session of the Grand Rounds, the physicians had a deeper conversation about the patient's diagnosis and treatments.
MORE Health was honored to be invited to join the Grand Rounds. During the sessions, Dr. Zhong and Dr. Chen were impressed by the effectiveness of MORE Health's Co-diagnosis Platform, the efficiency of its medical team, and its resources of US physicians.
The US physicians who participated in the event also expressed their passion and interest in academic communications with physicians in China to better serve Chinese patients through MORE Health's platform.
